Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jennifer Arrondeau"'
Autor:
David Balakirouchenane, Sarah Guégan, Chantal Csajka, Anne Jouinot, Valentine Heidelberger, Alicja Puszkiel, Ouidad Zehou, Nihel Khoudour, Perrine Courlet, Nora Kramkimel, Coralie Lheure, Nathalie Franck, Olivier Huillard, Jennifer Arrondeau, Michel Vidal, Francois Goldwasser, Eve Maubec, Nicolas Dupin, Selim Aractingi, Monia Guidi, Benoit Blanchet
Publikováno v:
Cancers, Vol 12, Iss 4, p 931 (2020)
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patient
Externí odkaz:
https://doaj.org/article/a08b6b4f2c8f41e8b63e6ca0706be129
Autor:
Perrine Courlet, David Balakirouchenane, Nora Kramkimel, Jennifer Arrondeau, Selim Aractingi, Alicja Puszkiel, Monia Guidi, Eve Maubec, Valentine Heidelberger, Chantal Csajka, Olivier Huillard, Anne Jouinot, Ouidad Zehou, François Goldwasser, Nihel Khoudour, C. Lheure, Michel Vidal, Nathalie Franck, Nicolas Dupin, Benoit Blanchet, Sarah Guégan
Publikováno v:
Cancers, vol. 12, no. 4
Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 931, p 931 (2020)
Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 931, p 931 (2020)
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb1aa583bb97d9a0e23e0f770600a18
https://serval.unil.ch/resource/serval:BIB_E1BBC7ED0901.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_E1BBC7ED0901.P001/REF.pdf
Autor:
Laurence Weiss, Constance Thibault, François Goldwasser, Jennifer Arrondeau, Mariana Mirabel, Stéphane Oudard, Audrey Mansuet-Lupo, Anastasia Saade
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Background Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent u
Autor:
Sarah Guégan, François Goldwasser, Nathalie Franck, Nora Kramkimel, Anne Jouinot, Valentine Heidelberger, Nicolas Dupin, Selim Aractingi, Jérôme Alexandre, Jennifer Arrondeau, Audrey Mansuet-Lupo, Diane Damotte, Marie-Françoise Avril
Publikováno v:
Investigational New Drugs. 35:842-847
Background The identification of the melanoma patients sensitive to anti-PD-1 inhibitors, nivolumab or pembrolizumab, is a major therapeutic challenge and an urgent need. We hypothesized that the natural history of the disease might partly reflect th
Autor:
Jennifer Arrondeau, François Goldwasser, Gervais Claire, Jérôme Biton, Franck Letourneur, Marco Alifano, Pascaline Boudou-Rouquette, Sarah H. Warren, Karen Leroy, Alessandra Cesano, Audrey Bellesoeur, Nora Kramkimel, P Morel, Angéline Duché, Hanane Ouakrim, Xing Ren, Audrey Lupo, Diane Damotte
Publikováno v:
Cancer Research. 78:4546-4546
Purpose of the study : The 18-gene Tumor Inflammation Signature (TIS) (Ayers et al, J Clin Invest 2017; 127:2930) is a clinical research assay that enriches for clinical response to immune checkpoint blockade. In this work, the performance of the TIS
Autor:
Selim Aractingi, V. Heidelberger, Jérôme Alexandre, Nicolas Dupin, Benoit Blanchet, Jennifer Arrondeau, Johan Chanal, N. Franck, P. Boudou Rouquette, F. Goldwasser, Olivier Huillard, Nora Kramkimel
Publikováno v:
Annals of Oncology. 27:vi387
Autor:
Benoît, Rousseau, Stéphane, Champiat, Delphine, Loirat, Jennifer, Arrondeau, Nathalie, Lemoine, Jean-Charles, Soria
Publikováno v:
Bulletin du cancer. 101(1)
New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipili